Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 28.530
Filtrar
1.
Georgian Med News ; (318): 114-119, 2021 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-34628390

RESUMO

The aim of the study was to study the level of vitamin D in menopausal women living in Kvemo Kartli region; to determine the relationship between various factors and vitamin D deficiency; to formulate recommendations about efficient preventive activities based on epidemiologic study results. Research methods and materials: Cross-sectional (prevalence) research was conducted in three different medical institutions in Rustavi with a high number of patients. The study population involved women aged 47-54 years who had not received vitamin D supplements or other food supplements in the last 2 months. The research was conducted using standard questionnaire, which revealed various factors affecting the level of vitamin D, as well as Demographic characteristics. Half of the study population underwent blood vitamin D screening in late autumn, the other half in spring. The study showed that 24% of the menopausal women involved in our study, living in Kvemo Kartli had adequate levels of vitamin D (≥30 ng/ml), and 76% of the women had vitamin D deficiency/insufficiency in the blood. The majority -90% of those diagnosed with vitamin D deficiency are urban residents, 77% of respondents with adequate levels of vitamin D in the blood do physical work. At the same time, none of the respondents working in the open space and ethnically Azerbaijani and examined in the fall had a deficiency of vitamin D in their blood. A statistically significant correlation was found between the risk factors, we had assessed and the presence of vitamin D deficiency: Correlation Between the season of determining the level of vitamin D in the blood and the level of vitamin D, in particular, the chance of having a deficiency of vitamin D in the blood in spring is 11 times higher than in autumn (odds ratio (OR) =11.3 95% CI (1.4-90.6); Correlation Between the type of work (less physical activity) and vitamin D deficiency (OR) = 3.5 95% CI (1.1-12.6), 77% of respondents with adequate levels of vitamin D in the blood do physical type of work. work with less physical activity); Correlation between dress style (closed garments and headscarves) and vitamin D deficiency (OR) = 8.0 95% CI (1.0 -64.1). Considering the correlation with the above-mentioned issues related to vitamin D deficiency, special attention should be paid to different factors contributing to vitamin D deficiency/ insufficiency in menopausal women, such as the degree of exposure to the sun and various aspects related to it, evaluation and prevention of vitamin D deficiency prevalence.


Assuntos
Deficiência de Vitamina D , Vitamina D , Estudos Transversais , Feminino , Humanos , Menopausa , Deficiência de Vitamina D/epidemiologia , Vitaminas
2.
BMC Womens Health ; 21(1): 348, 2021 10 04.
Artigo em Inglês | MEDLINE | ID: mdl-34607596

RESUMO

BACKGROUND: While women are taking a greater role in decisions about menopause symptom management, the legacy of the Women's Health Initiative (WHI) studies persist. Despite hormone therapy (HT) being effective in reducing all-cause mortality, many women seeking relief of menopausal symptoms exaggerate HT harms and overstate the perceived benefits or ignore the risks of alternative therapies. We aimed to explore the longitudinal impact of the widely-publicised WHI 2002 study on women's information-seeking and describe determinants of decision-making about managing menopausal symptoms. METHODS: In a longitudinal analysis of both quantitative and qualitative data, we explored consumer questions about menopause-related medicines received by two Australian medicines call centres (1996-2010) before, during, and after WHI 2002. We analysed calls by age and gender of caller and patient, their relationship, postcode, enquiry type, and motivation to help-seek. We compared calls regarding HT and herbal medicines (HM) with the rest of calls, and thematically analysed question narratives across the three time-periods. RESULTS: There were 1,829 menopause-related calls received of over this time-period, with a call surge, primarily from women in their mid-fifties, in the two months after the WHI 2002 publication. Two in three calls were motivated by negative media reports as women sought support for decision-making, primarily reassurance to cease HT. While HT safety concerns persisted for eight years post-publication, the nature of information-seeking changed over time. Callers subsequently sought reassurance to use menopause treatments together with their other medicines; and pursued HT substitutes, including HM, in response to HT product discontinuation. CONCLUSIONS: Women sought information or reassurance to support a decision, based on dynamic changes in internal (symptom or risk intolerance, attitude towards menopause and treatment preferences) and external factors (perceived source trust and changes in treatment availability). In assessing HT benefit versus risk, women tend to overestimate risk with HT safety concerns persisting over time. Decision-making in managing menopause symptoms is complex and dynamic. Reassurance to reach or justify decisions from a perceived trusted source can support informed decision-making.


Assuntos
Call Centers , Comportamento de Busca de Informação , Austrália , Terapia de Reposição de Estrogênios , Feminino , Humanos , Menopausa , Saúde da Mulher
3.
Rev Med Suisse ; 17(749): 1521-1525, 2021 Sep 08.
Artigo em Francês | MEDLINE | ID: mdl-34495588

RESUMO

Urinary incontinence is a common urological condition. It is classified into several subtypes, among which most frequently encountered are stress, urgency and mixed incontinence. Urinary continence depends on many physiological factors, some of which can potentially be influenced by numerous medications. The most commonly implicated drugs in urinary incontinency are antipsychotics, antidepressants, benzodiazepines, alpha blockers, diuretics, and hormone replacement therapy for menopause. Although the prescription of these types of drugs continues to increase, their effect on continence has received little attention from prescribers.


Assuntos
Preparações Farmacêuticas , Incontinência Urinária por Estresse , Incontinência Urinária , Feminino , Humanos , Menopausa , Incontinência Urinária/induzido quimicamente , Incontinência Urinária/tratamento farmacológico , Incontinência Urinária/epidemiologia , Incontinência Urinária de Urgência
4.
Ther Umsch ; 78(8): 407-411, 2021.
Artigo em Alemão | MEDLINE | ID: mdl-34555966

RESUMO

Desire to have children in the menopausal transition Abstract. The menopausal transition is characterized by the loss of ovarian reserve, i. e. the number and quality of oocytes. This impairment results in a quick and massive decline in female fecundity. Ovarian reserve can be determined with the measurement of FSH and AMH in the serum plus the count of the sonographically visible follicles (antral follicle count; AFC). Therapeutically the desire to have children can be fulfilled by using homologous fertility treatments such as monofollicular ovarian stimulation and In Vitro Fertilization. More promising, however, is heterologous egg donation. As a preventive measure Social Egg Freezing is utilized increasingly.


Assuntos
Hormônio Antimülleriano , Reserva Ovariana , Criança , Feminino , Humanos , Menopausa , Folículo Ovariano , Indução da Ovulação
5.
Ther Umsch ; 78(8): 413-420, 2021.
Artigo em Alemão | MEDLINE | ID: mdl-34555968

RESUMO

Modern management of the genitourinary syndrome of menopause (GSM) Abstract. Genitourinary syndrome of menopause (GSM) affects up to more than 80 % of postmenopausal women. The diagnosis is purely clinical. Differential diagnosis may require additional laboratory diagnostics. Many therapeutic options are now available internationally (hormone-free vaginal preparations, hormone-containing vaginal preparations, vaginal laser). The choice of therapy depends on the severity of symptoms, the effectiveness and safety of treatments for the individual patient, and the patient's preferences. Long-term studies of the endometrial safety of vaginal estrogen and vaginal dehydroepiandrosterone (DHEA) are not available. Therapy should be continued as long as necessary, i. e., possibly for life. Although the data on hormonal vaginal preparations in breast cancer are insufficient, the international scientific societies are now more open to the use of vaginal estrogen and DHEA.


Assuntos
Menopausa , Vagina , Feminino , Humanos , Síndrome
6.
Ther Umsch ; 78(8): 465-471, 2021.
Artigo em Alemão | MEDLINE | ID: mdl-34555969

RESUMO

MHT: Who benefits? Who does not benefit? Abstract. Individually adapted MHT with respect of known contra-indications possess direct preventive health effects. Moreover, reducing the incidence of diab. mell. type II further secondary preventive effects can be expected.


Assuntos
Terapia de Reposição de Estrogênios , Menopausa , Medicamentos de Ervas Chinesas , Feminino , Humanos , Incidência
7.
Ther Umsch ; 78(8): 457-464, 2021.
Artigo em Alemão | MEDLINE | ID: mdl-34555970

RESUMO

MHT: How and how long in healthy women above 65? Abstract. In Europe, women spend more than one third of their lifetime in the postmenopause which is characterized by chronic estrogen deficiency. About 80 % of them suffer from vasomotor symptoms which can last for up to twelve years or more. Menopausal hormone therapy (MHT) with sexual steroids is the most effective treatment resulting in a reduction of hot flushes and an improvement of quality of life. Today, a large proportion of women is not treated adequately as demonstrated by a marked decline of MHT-prescriptions. The postmenopause is not only associated with climacteric symptoms, but also with long-term risks, such as cardiovascular events, osteoporosis, cognitive dysfunction or diabetes mellitus. Numerous studies have shown beneficial effects of MHT on many of these diseases and on mortality, provided that treatment has been initiated close to the onset of menopause. Accordingly, some investigators have postulated a possible role of MHT in primary prevention. However, concerning long-term beneficial effects of MHT in women beyond the age of 65 years, the optimal duration of MHT is still unknown. Consequently, the duration of MHT should always be planned individually after thorough consideration of potential benefits and risks in agreement with the patient. Especially with advancing age transdermal application of estrogens seems to be the best option because of less vascular risks. There is no apodictic limitation of maximal duration of MHT.


Assuntos
Terapia de Reposição de Estrogênios , Qualidade de Vida , Idoso , Estrogênios , Feminino , Humanos , Menopausa , Pós-Menopausa
8.
Ther Umsch ; 78(8): 483-485, 2021.
Artigo em Alemão | MEDLINE | ID: mdl-34555971

RESUMO

Menopausal Hormone Therapy in women with other underlying diseases: how to proceed? Abstract. Postmenopausal women frequently suffer, in addition to classical climacteric symptoms, from other diseases. Therefore, it is important to know when, in which form, and with which dosage menopausal hormone therapy (MHT) may be prescribed with regard to the underlying chronic disease. All women's health specialists have to know when MHT is contraindicated. To minimize the risks of MHT in the presence of a chronic disease, the following basic rules should be kept in mind: If there is no absolute contraindication, MHT should be started within the "window of opportunity" (age < 60 years or within 10 years of menopause). Continuous transdermal administration has to be preferred; in the presence of most chronic diseases, a hepatic first pass effect should be avoided. The lowest efficient dosage should be selected because most side effects are dose dependent. Cyclical fluctuations of hormone blood levels should be avoided. Metabolically neutral progestagens, such as micronized progesterone, dydrogesterone and dienogest or transdermal administration of norethisterone acetate (NETA) should be chosen. Medroxyprogesterone acetate has to be avoided. If there are doubts, the treating physician should be contacted. Angiopathies (e. g., in arterial hypertension, diabetes mellitus, lupus erythomatodes) are an absolute contraindication for MHT. In the absence of angiopathies, transdermal MHT might be prescribed in women suffering from these diseases after an extensive risk-benefit evaluation and in agreement with the treating physician.


Assuntos
Terapia de Reposição Hormonal , Doenças Vasculares , Administração Cutânea , Terapia de Reposição de Estrogênios/efeitos adversos , Feminino , Humanos , Menopausa , Pessoa de Meia-Idade , Saúde da Mulher
9.
Ther Umsch ; 78(8): 473-481, 2021.
Artigo em Alemão | MEDLINE | ID: mdl-34555973

RESUMO

Evidence-based Facts of non-hormonal treatment of menopausal symptom Abstract. Menopausal symptoms like hot flushes and night sweats can have a great impact on quality of life. As first line, hormonal therapy with estrogens in combination with progestins is used, and shows beneficial effects on these symptoms. Some women, however, have contraindications against hormonal therapy or do not wish to take hormones at all. In these women, alternative treatments are needed to treat vasomotor symptoms. Pharmacologic substances like antidepressants, anticonvulsants or antihypertensive drugs show a significant reduction of these symptoms in menopausal women. Phytopharmaceutical products may show beneficial effects but study designs often do not fulfil strict scientific criteria. Furthermore, dosage and composition of the products may differ considerably. Best data are available for isoflavons and extracts of cimicifuga racemosa. Other alternative therapies like yoga, exercise, hypnosis and acupuncture showed promising results in small studies and may be recommended individually.


Assuntos
Qualidade de Vida , Sudorese , Exercício Físico , Feminino , Fogachos/tratamento farmacológico , Humanos , Menopausa
10.
Ther Umsch ; 78(8): 435-439, 2021.
Artigo em Alemão | MEDLINE | ID: mdl-34555974

RESUMO

Update on fracture prevention after menopause Abstract. Osteoporosis is a common disease. It is multifactorial and polygenetic in pathogenesis as well as clinically underdiagnosed and undertreated. There are several medical specialties involved in the care of female osteoporosis patients. "Gate keepers" of all female osteoporosis patients are the gynecologists, because they see the patient at the onset of menopausal symptoms, which may be indicative of accelerated bone loss. It is important to plan therapy with different sequences, one of which may be gynecologically recommended hormone therapy. Since osteoporosis is a chronic disease in the vast majority of cases, long-term therapy and patient retention is essential.


Assuntos
Ginecologia , Osteoporose , Feminino , Humanos , Menopausa
11.
Ther Umsch ; 78(8): 427-434, 2021.
Artigo em Alemão | MEDLINE | ID: mdl-34555975

RESUMO

Climacteric depression and anxiety Abstract. Women of all ages have a higher incidence of depression than men. The lifetime prevalence of depressive disorders in women is twice the prevalence in males and amounts to 18 - 21 %. The menopausal transition is a "window of increased vulnerability" and might trigger a depressive disorder. In this period, the risk to get depressive is 1.5 - 4 times higher than in the premenopause, particularly in women suffering from vasomotor symptoms and presenting additional risk factors for mood disorders and depression. Depression in climacteric women is still underestimated and has to be actively looked for by family doctors and gynaecologists. Oestrogens modulate the metabolism of serotonin and noradrenalin, as do SSRI / SNRI and antidepressants, and influence therefore mood, mental function and cognition. In the menopausal transition, there is suggestive evidence that Oestrogen therapy can improve mood, anxiety and depression. In peri- and early postmenopausal women with climacteric vasomotor symptoms, Oestrogens might be considered as a first-line treatment for depressive symptoms. However, Oestrogens do not improve depression in the late postmenopause. In depressed elderly postmenopausal women without hot flushes, SSRI / SNRI and antidepressants remain the first-line treatment. Each pharmacological treatment should always be embedded in a global therapeutic concept including among others frequently psychotherapy and social measures.


Assuntos
Climatério , Depressão , Idoso , Ansiedade , Transtornos de Ansiedade/diagnóstico , Transtornos de Ansiedade/tratamento farmacológico , Feminino , Humanos , Masculino , Menopausa
12.
Ther Umsch ; 78(8): 447-455, 2021.
Artigo em Alemão | MEDLINE | ID: mdl-34555976

RESUMO

Clinical evaluation of progestogens used in Menopausal Hormone Therapy (MHT) Abstract. Primary indication for progestogens in MHT is to avoid estrogen-induced endometrial cancer. Progesteron has the least endometrial efficacy but is used increasingly (together with transdermal estradiol) because it is neutral in vascular and metabolic systems and possibly may have a lower risk of breast cancer. Comparable is dydrogesterone, the retro-isomer of progesterone, but with higher endometrial efficacy. However, also other progestogens (including tibolone) are used to take advantage of the androgenic, anti-androgenic and anti-mineralocorticoid "partial effects". Based on the results of the Women's Health Initiative Study the use of progestogens in MHT can cause an increased risk of breast cancer and coronary artery disease. Using different progestogens this is confirmed in various observational studies, which also suggest an increased progestogen-dependent risk of stroke. Since with every MHT early start can reduce cardiovascular risk or even act preventive, the decisive question remains, if there may be a screening regarding already known mechanisms for hormone-dependent development of breast cancer, at least for patients with increased risk of breast cancer. For this, new own research results are described.


Assuntos
Neoplasias da Mama , Progestinas , Neoplasias da Mama/induzido quimicamente , Terapia de Reposição de Estrogênios/efeitos adversos , Estrogênios/efeitos adversos , Feminino , Humanos , Menopausa , Progestinas/efeitos adversos
13.
Ther Umsch ; 78(8): 441-446, 2021.
Artigo em Alemão | MEDLINE | ID: mdl-34555977

RESUMO

Endometriosis and Menopause Abstract. Endometriosis is supposed to affect only women in their reproductive years, but endometriotic lesions can reactivate in menopause and cause significant complaints in these patients. Altered needs and co-morbidities of the women request a different approach in therapy than in the younger ages. Reduction in chronic pain on the one hand and alleviation of climacteric symptoms, like hot-flushes and vaginal dryness, on the other hand, are main concerns to the physician in charge. Consequently, keeping the balance between the hypoestrogenic state, which is necessary to reduce activity and size of endometriotic lesions, and hormone replacement therapy (HRT) to relief menopausal complaints, depicts the key in treating these women. Progesterons, GnRH-analoga (with addback) and intrauterine devices depict the basic therapeutic strategy in perimenopausal women. In case of uncertain sonographic findings or intractable symptoms, a surgical approach (and histology) should be performed. Aromatase inhibitors, melatonin, oral GnRH-antagonists and ablation of the endometrium (in bare dysmenorrhea) represent promising alternatives to the established therapy. Requesting an HRT, it is important to add progesterone for at least two years, even in the patients with a prior hysterectomy to avoid a recurrence of residual lesions.


Assuntos
Endometriose , Endometriose/diagnóstico , Endometriose/terapia , Feminino , Humanos , Menopausa
14.
Adv Ther ; 38(10): 5025-5045, 2021 10.
Artigo em Inglês | MEDLINE | ID: mdl-34514552

RESUMO

INTRODUCTION: Hot flushes/flashes (HFs) or other vasomotor symptoms affect between 45 and 97% of women during menopause. Hormone replacement therapy (HRT) is effective at alleviating menopausal symptoms, but some women cannot or prefer not to take HRT. Since current non-hormonal options have suboptimal efficacy/tolerability, there is a pressing need for an effective, well-tolerated alternative. The neurokinin 3 receptor (NK3R) has recently been implicated in the generation of menopausal HFs and represents a novel therapeutic target to ameliorate HF symptoms. This review aims to assess if NK3R antagonists (NK3Ras) are more effective than Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)-currently a common choice for non-hormonal treatment of menopausal HFs. METHODS: Studies were identified after systematically searching Ovid MEDLINE and EMBASE databases based on PRISMA guidelines. Trial quality and bias were assessed. Key efficacy outcomes (HF frequency, HF severity and number of night-time awakenings/night-sweats) and selected safety outcomes were extracted and analysed. RESULTS: Seven SNRI and four NK3Ra placebo-controlled randomised trials (plus four follow-up reports) were included in this review. NK3Ra administration resulted in a larger reduction from baseline in HF frequency, HF severity and night-sweats compared to SNRIs. Five of seven SNRI trials showed a reduction in HF frequency that was statistically significant (by 48-67% from baseline at weeks 8 or 12) whereas all NK3Ra trials showed a statistically significant reduction in HF frequency (by 62-93% from baseline at weeks 2, 4 or 12). While SNRI trials reported poor tolerability, particularly nausea, NK3Ra trials reported good tolerability overall, although two trials reported elevation in transaminases. CONCLUSION: NK3Ras trials show encouraging efficacy and tolerability/safety. Completion of phase 3 NK3Ra trials are required to confirm efficacy and uphold safety/tolerability data but phase 2 results suggest that NK3Ras are more effective than SNRIs for non-hormonal treatment of menopausal HFs.


Assuntos
Inibidores de Captação de Serotonina , Serotonina , Feminino , Humanos , Menopausa , Norepinefrina , Receptores da Neurocinina-3 , Inibidores de Captação de Serotonina/uso terapêutico
15.
Rev Colomb Obstet Ginecol ; 72(2): 162-170, 2021 06 30.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-34506703

RESUMO

Objective: To make an approximation to the prevalence of sleep disorders in Colombian menopausal women during the COVID-19 pandemic Materials and Methods: Cross-sectional study as part of the Quality of Life in Menopause and Colombian Ethnic Groups research project [CAVIMEC+COVID STUDY]. The population consisted of women born and residing in Colombia, 40 to 59 years of age, who signed an informed consent and agreed to participate by completing an online form, freely and anonymously, in the first five days of June 2020. Sleep disorders were identified using the third item on the Menopause Rating Scale. Sociodemographic characteristics, presence and severity of sleep disorders and menopause status were explored. Descriptive statistics are provided. Results: Overall, 984 women aged 47.0 [IQR: 42.0-53.5] years were included: 84.5% mestizo, 13.7% Afro-Colombian, 1.7% indigenous; 39.3% were postmenopausal; 70% lived in the Caribbean region of Colombia. Sleep disorders were reported by 637 women (64.7%), and 112 (11.3%) had severe sleep disorders. Among postmenopausal women, 65.1% reported sleep disorders with 10.1% reporting severe disorders, while 64.5% of premenopausal reported sleep disorders, and 12.2% severe disorders. Conclusions: Sleep disorders could be a frequent problem among premenopausal as well as postmenopausal women in the pandemic time. This issue should be explored during gynecological visits in order to offer solutions. Population studies that confirm these observations are required.


Assuntos
COVID-19 , Transtornos do Sono-Vigília/epidemiologia , Adulto , Colômbia/epidemiologia , Estudos Transversais , Feminino , Humanos , Menopausa , Pessoa de Meia-Idade , Prevalência
16.
PLoS One ; 16(9): e0257051, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34506535

RESUMO

It has been widely observed that adult men of all ages are at higher risk of developing serious complications from COVID-19 when compared with women. This study aimed to investigate the association of COVID-19 positivity and severity with estrogen exposure in women, in a population based matched cohort study of female users of the COVID Symptom Study application in the UK. Analyses included 152,637 women for menopausal status, 295,689 women for exogenous estrogen intake in the form of the combined oral contraceptive pill (COCP), and 151,193 menopausal women for hormone replacement therapy (HRT). Data were collected using the COVID Symptom Study in May-June 2020. Analyses investigated associations between predicted or tested COVID-19 status and menopausal status, COCP use, and HRT use, adjusting for age, smoking and BMI, with follow-up age sensitivity analysis, and validation in a subset of participants from the TwinsUK cohort. Menopausal women had higher rates of predicted COVID-19 (P = 0.003). COCP-users had lower rates of predicted COVID-19 (P = 8.03E-05), with reduction in hospital attendance (P = 0.023). Menopausal women using HRT or hormonal therapies did not exhibit consistent associations, including increased rates of predicted COVID-19 (P = 2.22E-05) for HRT users alone. The findings support a protective effect of estrogen exposure on COVID-19, based on positive association between predicted COVID-19 with menopausal status, and negative association with COCP use. HRT use was positively associated with COVID-19, but the results should be considered with caution due to lack of data on HRT type, route of administration, duration of treatment, and potential unaccounted for confounders and comorbidities.


Assuntos
COVID-19/epidemiologia , Terapia de Reposição de Estrogênios , Estrogênios/metabolismo , Menopausa/metabolismo , Adulto , Estudos de Coortes , Comorbidade , Feminino , Humanos , Pessoa de Meia-Idade , Fatores de Risco , Reino Unido
17.
Hist Philos Life Sci ; 43(3): 103, 2021 Aug 24.
Artigo em Inglês | MEDLINE | ID: mdl-34427800

RESUMO

Menopause is an evolutionary mystery: how could living longer with no capacity to reproduce possibly be advantageous? Several explanations have been offered for why female humans, unlike our closest primate relatives, have such an extensive post-reproductive lifespan. Proponents of the so-called "grandmother hypothesis" suggest that older women are able to increase their fitness by helping to care for their grandchildren as allomothers. This paper first distinguishes the grandmother hypothesis from several other hypotheses that attempt to explain menopause, and then develops a formal model by which these hypotheses can be compared and tested by empirical researchers. The model is then modified and used to respond to a common objection to the grandmother hypothesis: that human fathers, rather than grandmothers, are better suited to be allomothers due to their physical strength and a high incentive to invest in their own children. However, fathers-unlike maternal grandmothers-can never be sure that the children they are caring for are their own. Incorporating paternity uncertainty into the model demonstrates the conditions under which the grandmother hypothesis is more plausible than a hypothesis that focuses on the contributions of men.


Assuntos
Família , Avós , Menopausa , Modelos Biológicos , Feminino , Aptidão Genética , Humanos
18.
BMC Public Health ; 21(1): 1599, 2021 08 30.
Artigo em Inglês | MEDLINE | ID: mdl-34461857

RESUMO

BACKGROUND: Body image is the main element of an individual's personality that may be influenced by many factors during menopause. We aimed to assess the relationship between postmenopausal women's body image with the severity of menopausal symptoms. METHODS: This was a cross-sectional study on 300 postmenopausal women, aged 45 to 65 years old, in Tehran, Iran. We recruited the samples using the multi-stage sampling method. Tools for data collection were: 1) the Menopausal Rating Scale (MRS), 2) the Fisher's Body Image questionnaire and 3) a socio-demographic questionnaire. We analyzed data using the independent samples t-test, Pearson correlation coefficient, Spearman's correlation coefficient, and multiple linear regression tests. RESULTS: Three hundred women aged 55.11 ± 3.99 years old, participated in the study. Mean scores for body image and MRS were 163.07 ± 21.17 (Range: 46-230) and 16.45 ± 8.38 (Range: 0-44), respectively. About 50% of women had severe symptoms of menopause (MRS score ≥ 17). There was a negative correlation between the total score and the score of all dimensions of body image with the total score and all dimensions of MRS (P < 0.001). There were also significant relationships between women's body image with: their education (P < 0.001, r = 0.20) the spouse's education (P < 0.001, r = 0.26), adequacy of monthly household income (P < 0.001, r = 0.32), marital status (P = 0.36), their occupation (P = 0.007) and housing status (P = 0.012). There was also a significant negative correlation between women's lower body organs image with the number of children (P = 0.017, r = - 0.14). According to the multiple linear regressions model, severity of menopausal symptoms (Beta = - 0.45, P < 0.001) and adequacy of monthly household income (Beta = 0.15, P = 0.005) are the significant related factors with postmenopausal women's body image. CONCLUSIONS: Body image is correlated with menopausal symptoms of women during menopause. Therefore, it seems that interventions aimed at relieving the annoying symptoms of menopause can help to improve their body image. Also, body image could be influenced by some socio-demographic factors which should be considered in menopause health promotion programs.


Assuntos
Imagem Corporal , Pós-Menopausa , Idoso , Estudos Transversais , Feminino , Fogachos , Humanos , Irã (Geográfico)/epidemiologia , Menopausa , Pessoa de Meia-Idade , Inquéritos e Questionários
19.
Zhonghua Yu Fang Yi Xue Za Zhi ; 55(8): 1006-1010, 2021 Aug 06.
Artigo em Chinês | MEDLINE | ID: mdl-34445841

RESUMO

To explore the mode of"one-day outpatient"based continuous management and examine its feasibility and preliminary effects for improving menopausal syndrome and mood among menopausal women.Clinical intervention study was conducted in Obstetrics and Gynecology Center of the Third Affiliated Hospital of Chongqing Medical University from May 2020 to May 2021.The continuous management mode of "one-day outpatient service" for menopause was constructed in terms of multidisciplinary resources, including offline "one-day outpatient" health education, online 7-week group continuous intervention on "healthy lifestyle" and offline half-day focus group interview. Pre-and post-scores of the modified Kupperman scale and the positive/negative emotional scale (PANAS) were measured to compare the status of menopausal syndrome and emotional experience of Seventy-eight female participants (40-60 years old), meanwhile, before and after comparison of the blood lipid and body composition indexes of participants were also performed. Paired t test or Wilcoxon signed rank test were used.Results show that the pre-and post Kupperman scores were 14.65±8.51 vs 10.26±5.83 (t=-5.59, P<0.01), and the positive emotional scores (pre- 28.53±5.85 vs post- 30.13±6.30) were improved (t=2.59, P=0.012) and negative emotional scores [pre- 20.5(10) vs post- 17.0(7)] were decreased (Z=-5.09, P<0.01). The triglyceride level of participants declined from (1.27±0.54) mmol/L to (1.09±0.38) mmol/L (t=-2.45, P<0.05). In addition, the body mass index(pre- 22.52±2.34 vs post- 22.06±2.22), percentage of body fat (pre- 31.72±6.22 vs post- 30.91±6.52)and Visceral fat area(pre- 83.96±30.26 vs post- 79.66±29.71) were all improved (t=-3.58,t=-2.57,t=-2.59, P<0.05). Therefore,the mode of"one-day outpatient"based continuous management can effectively improve menopausal syndrome and adverse mood, reduce patients' blood lipid, improve the body composition, and maybe contribute to the prevention of long-term chronic diseases.


Assuntos
Menopausa , Pacientes Ambulatoriais , Adulto , Composição Corporal , Índice de Massa Corporal , Estudos de Viabilidade , Feminino , Humanos , Pessoa de Meia-Idade
20.
Medicine (Baltimore) ; 100(31): e26715, 2021 Aug 06.
Artigo em Inglês | MEDLINE | ID: mdl-34397808

RESUMO

BACKGROUND: Various bisphosphonate agents have been proven to be effective in preventing bone loss and fracture in osteopenic postmenopausal women. This study was designed to compare the effectiveness of various BPs on preventing the loss of bone mineral density (BMD) for postmenopausal women with osteopenia. METHODS: PubMed, EMBASE, and Cochrane Central Register of Controlled Trials were screened up to identify randomized controlled trails comparing effectiveness of BPs or placebo on the BMD of postmenopausal women with osteopenia. Network meta-analysis and standard pair-wise meta-analyses were performed. The main outcomes include the percentage changes of 6-, 12-, 24-, and 36-month BMD at lumbar, total hip and femoral neck, and frequencies of new fractures and severe adverse events. RESULTS: Fourteen randomized controlled trials were eligible, involving 11,540 participants. No significant difference was presented among the available interventions for the 6-month BMD at 3 different sites, but the magnitudes of differences among the treatment regimens became gradually increased along with the extending of follow-up periods. Daily aledronate of more than 5 mg provided the maximal percentage increase on BMD of femoral neck and lumbar spine, while zoledronate provided maximal change on BMD of total hip, at different follow-up periods. This network meta-analysis also demonstrated similar frequencies of new clinical fractures and severe adverse events among different interventions. CONCLUSIONS: A ranking spectrum depicting the effectiveness on BMD percentage change following interventions with different bisphosphonate regimens was provided. Generally, regimens with zoledronate and aledronate were found to be the most effective interventions in the 3 sites at different end points.


Assuntos
Densidade Óssea/efeitos dos fármacos , Difosfonatos/normas , Conservadores da Densidade Óssea/farmacologia , Conservadores da Densidade Óssea/normas , Difosfonatos/farmacologia , Humanos , Menopausa/efeitos dos fármacos , Menopausa/fisiologia , Metanálise em Rede , Ensaios Clínicos Controlados Aleatórios como Assunto/estatística & dados numéricos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...